Clinical trials
Autoimmune Liver Disease clinical trials
Below are recruiting autoimmune liver disease clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT05810480Recruiting
Predicting steroid-dependent liver injury with blood test
This study looks at whether a specific blood marker can predict which patients with liver inflammation will need long-term steroid treatment. It may help doctors decide the best treatment for you if you have unexplained liver injury.
AachenAges Any age - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Palo Alto, CaliforniaAges Any age - NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT03175471Recruiting
MRI study of blood-vessel and tissue signs in child liver disease
This trial uses MRI scans to look for “biomarkers,” which are measurable signs in the liver, to better understand autoimmune liver diseases in children and teens. It may help doctors track disease and improve care by finding imaging patterns linked to illness.
Cincinnati, OhioAges 6–23 - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT07791043RecruitingPhase 2
Efimosfermin alfa for alcohol-related liver disease
This study tests an investigational medicine called efimosfermin alfa to see if it is safe and effective for people with liver damage caused by heavy drinking. The medicine is compared to a placebo (a dummy treatment).
Topeka, KansasAges 18–75 - NCT07275736RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
BeijingAges 18–75 - NCT06825559RecruitingPhase 1
Saroglitazar safety in moderate liver impairment from cholestatic disease
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Indianapolis, IndianaAges 18–80 - NCT04106518Recruiting
Genetics study of alcohol-related liver disease and cirrhosis
This study looks at genetic differences in people with alcohol-related liver illness, including a recent jaundice episode (alcoholic hepatitis). By following people over time, it may help doctors better predict illness and understand why some people develop worse liver problems.
AngersAges 18 years+ - NCT01280825Recruiting
Testing how to use genetic medicine results in routine care
This study looks at how to put genetic testing results (pharmacogenomics) into regular doctor care. It aims to see whether using the results helps doctors choose safer, better-matched medications.
Chicago, IllinoisAges 18 years+ - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT07739914RecruitingPhase 3
Switching anti-rejection medicine after a liver transplant
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
Heidelberg, Baden-WurttembergAges 18–80 - NCT07359742Recruiting
Detecting liver scarring in chronic liver disease
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
BrusselsAges 18 years+ - NCT07452744Enrolling by invitation
Picroliv for non-alcoholic fatty liver disease
This study tests a plant-based medicine called Picroliv for people with non-alcoholic fatty liver disease (NAFLD). It aims to see if it is safe and can reduce fat in the liver.
Chandigarh, ChandigarhAges 18–60 - NCT04400604Recruiting
Study of liver disease risk from heavy alcohol use
This study looks at people with heavy alcohol use who may have alcohol-related liver damage. It aims to better understand liver disease risk and how it changes over time, using blood tests, some scans, and possibly stored tissue.
LilleAges 18–75 - NCT07699380RecruitingPhase 2
Metabolic therapy to improve insulin sensitivity in type 1 diabetes
This trial tests a drug that may help your body use insulin better and improve how your cells produce energy. It might lead to better blood sugar control and less insulin needed.
Seattle, WashingtonAges 18–69 - NCT07481734RecruitingPhase 2
Tesamorelin for reducing liver fat in fatty liver disease
This trial tests if tesamorelin, a daily injection, can reduce liver fat in adults with fatty liver disease. It may help people whose liver has fat but is not yet scarred into cirrhosis.
Shenzhen, GuangdongAges 18–75 - NCT07400367Recruiting
Probiotics and lifestyle changes for fatty liver disease
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
New Taipei CityAges 18–80 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT05919680RecruitingPhase 2
NST-6179 for liver disease from intestinal failure in adults
This Phase 2 study tests NST-6179 in people who have intestinal failure–associated liver disease (IFALD). It aims to improve liver function and overall outcomes for people whose liver inflammation and lab tests have been abnormal for at least 6 months.
Scottsdale, ArizonaAges 16 years+
Hear when a new Autoimmune Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune liver disease?
- Yes. Clin2 currently lists 177 recruiting autoimmune liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.